• Dupixent trial hits targets in adolescent atopic dermatitis pharmatimes
    July 12, 2018
    A late-stage study of Sanofi and Regeneron’s Dupixent in adolescents with atopic dermatitis has met its key targets, paving the way for a regulatory submission for drug targeting this younger patient group in the third quarter.
PharmaSources Customer Service